Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas - PubMed (original) (raw)
. 2001 Nov 15;61(22):8247-55.
Affiliations
- PMID: 11719457
Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas
R Wu et al. Cancer Res. 2001.
Abstract
Clinical and molecular findings suggest that the four major histological subtypes of ovarian carcinoma (serous, clear cell, mucinous, and endometrioid) likely represent distinct disease entities. Prior studies have shown that ovarian endometrioid adenocarcinomas (OEAs) often carry mutations in the CTNNB1 gene, which encodes beta-catenin, a critical component of the Wnt signaling pathway. However, the nature of other defects in the Wnt signaling pathway in ovarian carcinomas remains largely unknown. Thus, in 45 primary OEAs and two OEA-derived cell lines, we sought to comprehensively address the prevalence of and mechanisms underlying beta-catenin and Wnt pathway deregulation. CTNNB1 missense mutations were detected in 14 primary tumors. All mutations affected the NH(2)-terminal regulatory domain of beta-catenin, presumably rendering the mutant proteins resistant to degradation. Immunohistochemical studies revealed nuclear accumulation of beta-catenin in all but two tumors with CTNNB1 mutations. Two primary tumors lacking CTNNBI mutations showed strong nuclear immunoreactivity for beta-catenin. In one of the two tumors, biallelic inactivation of the APC gene was found. In the remaining 29 primary OEAs, unequivocal nuclear beta-catenin immunoreactivity was not observed, though a nonsense mutation in AXIN1 was observed in one tumor and a truncating frameshift mutation in AXIN2 was seen in another case. Both OEA-derived cell lines studied (TOV-112D and MDAH-2774) had elevated constitutive T-cell factor/lymphoid enhancer factor transcriptional activity. TOV-112D cells were shown to harbor mutant beta-catenin, whereas a missense AXIN1 sequence alteration was identified in MDAH-2774 cells. Collectively, our findings demonstrate frequent defects of the Wnt signaling pathway in a particular subtype of ovarian carcinomas, i.e., OEAs. Although mutations in the CTNNB1 gene are the most common mechanism of beta-catenin deregulation in OEAs, beta-catenin deregulation may also result from mutations in the APC, AXIN1, and AXIN2 genes.
Similar articles
- Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas.
Schwartz DR, Wu R, Kardia SL, Levin AM, Huang CC, Shedden KA, Kuick R, Misek DE, Hanash SM, Taylor JM, Reed H, Hendrix N, Zhai Y, Fearon ER, Cho KR. Schwartz DR, et al. Cancer Res. 2003 Jun 1;63(11):2913-22. Cancer Res. 2003. PMID: 12782598 - Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas.
Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, Cho KR. Hendrix ND, et al. Cancer Res. 2006 Feb 1;66(3):1354-62. doi: 10.1158/0008-5472.CAN-05-3694. Cancer Res. 2006. PMID: 16452189 - AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.
Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, Sasaki Y, Imaoka S, Murata M, Shimano T, Yamaoka Y, Nakamura Y. Satoh S, et al. Nat Genet. 2000 Mar;24(3):245-50. doi: 10.1038/73448. Nat Genet. 2000. PMID: 10700176 - beta-catenin signaling and cancer.
Morin PJ. Morin PJ. Bioessays. 1999 Dec;21(12):1021-30. doi: 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P. Bioessays. 1999. PMID: 10580987 Review. - [beta-catenin].
Ogawa K, Yaginuma Y. Ogawa K, et al. Nihon Rinsho. 2001 Oct;59 Suppl 6:161-6. Nihon Rinsho. 2001. PMID: 11761935 Review. Japanese. No abstract available.
Cited by
- Nuclear-cytoplasmic shuttling of Axin regulates subcellular localization of beta-catenin.
Cong F, Varmus H. Cong F, et al. Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2882-7. doi: 10.1073/pnas.0307344101. Epub 2004 Feb 23. Proc Natl Acad Sci U S A. 2004. PMID: 14981260 Free PMC article. - Wnt/β-Catenin Inhibition by CWP232291 as a Novel Therapeutic Strategy in Ovarian Cancer.
Wang W, Cho U, Yoo A, Jung CL, Kim B, Kim H, Lee J, Jo H, Han Y, Song MH, Lee JO, Kim SI, Lee M, Ku JL, Lee C, Song YS. Wang W, et al. Front Oncol. 2022 May 12;12:852260. doi: 10.3389/fonc.2022.852260. eCollection 2022. Front Oncol. 2022. PMID: 35646632 Free PMC article. - An analysis of polymorphisms within the Wnt signaling pathway in relation to ovarian cancer risk in a Polish population.
Mostowska A, Pawlik P, Sajdak S, Markowska J, Pawałowska M, Lianeri M, Jagodzinski PP. Mostowska A, et al. Mol Diagn Ther. 2014 Feb;18(1):85-91. doi: 10.1007/s40291-013-0059-y. Mol Diagn Ther. 2014. PMID: 24078348 Free PMC article. - Increased incidence of endometrioid tumors caused by aberrations in E-cadherin promoter of mismatch repair-deficient mice.
Kovtun IV, Harris KJ, Jatoi A, Jevremovic D. Kovtun IV, et al. Carcinogenesis. 2011 Jul;32(7):1085-92. doi: 10.1093/carcin/bgr080. Epub 2011 May 5. Carcinogenesis. 2011. PMID: 21551128 Free PMC article. - Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study.
Ring BZ, Murali R, Soslow RA, Bowtell DDL, Fereday S, deFazio A, Traficante N, Kennedy CJ, Brand A, Sharma R, Harnett P, Samimi G; Australian Ovarian Cancer Study. Ring BZ, et al. Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):680-688. doi: 10.1158/1055-9965.EPI-17-1101. Epub 2018 Mar 12. Cancer Epidemiol Biomarkers Prev. 2018. PMID: 29531130 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous